XENSE
OperatingXENSE INC
Healthcare · Irvine, DE · Founded 2018
META CT, first in the world. Minimize time to diagnosis, treatment and wellness
Financials
FY2020–FY2026 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round. Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth, so don't compare them with the other bars.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2024| Class | Outstanding | Votes / share | Share of total | Votes | Liquidation | Last price |
|---|---|---|---|---|---|---|
| Series Seed Preferred Stockpreferred | 401,212 | 1 | 1.09% | 0.21% | 1× non-participating · paid 1st | — |
| Class A Common Stock | 36,426,882 | 1 | 98.9% | 19.5% | — | — |
| Class B Common Stock | 10,000 | 15,000 | 0.03% | 80.3% | — | — |
| Total | 36,838,094 | 100% | 100% |
Principal holders% as the filing states it, May 2, 2025
- Ying Zhao8,331 Class B Common Stock83.3%of Class B
- Ying Zhao21,915,528 Class A Common Stock63.7%of Class A
Sold to the crowd
- Reg CF · Jun 2022$187.5K· 102 investors
- Reg CF · Sep 2024139,836 shares at $3.37$471.2K· 155 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
15 people
As the CEO, CTO and Founder of Xense Inc, Ms. Zhao has been involved in all phases of Xense’s development since its founding in 2018. She was a Vice President at Advanced Optical Technologies, Inc., where early concepts of the relevant technologies were developed. Ms Zhao is a vetted bioimaging visionary, having successful track records in trend forecast & developing high growth platform imaging systems for research, diagnostics and surgical guidance for global market leaders. Ms. Zhao is a published author, and an inventor of more than 70 patents, over 30 of which have been granted. She holds an M.S. in Electrical Engineering from Columbia University, an M.A. in Microbiology from Boston University, and a B.S. in Molecular and Cell Biology from the University of Connecticut. Ms. Zhao also serves as CEO of XENSELAB LLC, an IP holding company for XENSE Inc.
Mr. Bliss 's professional career began as an Electrical Engineer at Hughes Aircraft - Microelectronic Systems Division where he developed automated test software/hardware for military and commercial on-board (plane and ship) communication and entertainment systems. While working at Hughes Aircraft, Mr. Bliss was invited to join a start-up company, Procom Technology, as a Sr. Electrical Staff Engineer, designing and developing a family of performance-leading SCSI controllers, for their successful line of computer upgrade storage products. These evolved into high-end enterprise-class RAID and Network-Attached Storage (NAS) products. Mr. Alan Bliss was eventually Director of Hardware Engineering at Procom Technology, Inc., which was acquired by Sun Microsystems, Inc, and later on Oracle, where he successfully managed 150+ projects with multimillion dollar program budgets. Ms. Bliss has a BS in EE from California State Polytechnic University, Pomona.
Dr. Sean Lavine is an Investor of Xense. Dr. Lavine is a neurosurgeon / neuroradiologist and professor at Columbia University Medical Center. Dr. Lavine serves as a Director of Neuroendovascular Services at NewYork-Presbyterian Hospital/Columbia University Medical Center.Dr. Lavine has a BS from Weill Cornell Medical College, MD from Cornell University Medical College, Residency and Fellowship from USC Medical Center and NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Dr. Lavine was ranked as one of America’s Top doctors and one of New York’s Best Doctors.
Dr. Shafa completed a competitive 7 year accelerated B.A./M.D. program at The George Washington University, graduating in 2016. He completed a surgical internship at UCLA, 4 years of radiology residency at Jacobi Medical Center/Albert Einstein College of Medicine in New York, and returned to Los Angeles to complete neuroradiology fellowship at Cedars Sinai. His unique accomplishments include being author of a textbook, Learning Interventional Radiology, creator of iPhone educational app "Interventional Radiology," as well as sizeable social media following for radiology and medical education on Instagram and TikTok @Doctor.Justin
Dr. White is Chief of Musculoskeletal Radiology at University of Southern California – Keck University Hospital and Los Angeles County-USC Medical Center. He is also a musculoskeletal radiologist for USC athletes and director of Musculoskeletal Radiology fellowship, Prior to joining USC, Dr. White earned his medical degree from Jefferson Medical College. He completed his residency at Temple University. He was granted a fellowship in musculoskeletal/osteoradiology at University of Southern California. Dr. White is certified by the American Board of Radiology. He has been voted a “Top Doctor” by Pasadena Magazine in 2009, 2011, and 2012
Dr. Maslow is Chief Medical Officer of GeneOne Life Science Inc. GeneOne is a developer of gene-based therapies and vaccines. Dr. Maslow is currently leading development of vaccines highly virulent Emerging Infectious Diseases to include Covid virus including Sars-Covid -1 and SARS-CoV-2, Zika virus, MERS-CoV, Hepatitis C, and SFTS. Other products in development include DNA plasmid based therapies for Hemophilia A, obesity, breast cancer, and small molecular approaches to inflammatory diseases. He has extensive experience in clinical research and basic science research. Dr. Maslow has published extensively in the field of Emerging Infectious Diseases, HIV/AIDS, bacterial diseases, and Mycobacterial disease, such as tuberculosis and M. avium. Dr. Maslow was a Chief, Division of Infectious Diseases at Morristown Medical Center, and Professor of Medicine at University of Pennsylvania. Dr. Maslow has a MS in Physics from Drexel University. MD, from Jefferson Medical College, and Ph.D. in Physics from University of Virginia.
Mr. Mark Sitek is a radiation safety specialist in Cyclotron, Radiopharmacy, and Medical Health Physics. He is Radiation Safety Officer at VA Greater Los Angeles Healthcare System. Mr. Sitek was Radiation Inspector at San Onofre Nuclear Generating Stationand a Health Physicist/General Engineer at NRC Headquarters. Mr. Sitek has a BS in Nuclear Engineer from Rensselaer Polytechnic Institute, and a MS in Nuclear Engineering from Massachusetts Institute of Technology
Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS), and of Neurology.
A HHMI scholar and a scientist with 20+ years experience, Dr. Spanjaard’s federal and privately-funded translational research focused primarily on biomarker and drug discovery and was published in many high impact journals. Integrating technology with molecular biology to develop innovative devices that can solve unmet medical needs. Dr. Spanjaard cofounded Artemis Biosystems, a company that is developing a filtration device for viral vector bio manufacturing for gene therapy. Artemis Biosystems have funded collaborations with MIT, MassBiologics and industrial partners. Dr. Spanjaard is co-inventor on 2 granted patents for biomarkers and bio manufacturing. Dr. Spanjaard received his MA and PhD from Leiden University (Netherlands), and was a postdoc and Instructor at Harvard Medical School. He was a faulty member at Boston University School of Medicine, as Assistant Professor and Associate Professor.
Show 6 more peopleShow fewer
Mr. Steven Jensen is a partner at Knobbe Martens, the largest medical device IP firm in the US. Mr. Jensen ’s leadership of firm trial teams is extensive. Steve helped Masimo protect patient-monitoring technology. In one trial, a jury awarded over $134 million against Masimo’s primary rival. This victory helped propel Masimo to market success. In the second trial, Mr. Jensen and his trial team asserted Masimo’s patents against a patient-monitoring giant in the industry, where the jury awarded Masimo over $466 million. In addition, Mr. Jensen and his team also successfully defended Masimo against multiple claims of patent infringement. Mr. Jensen served on the Board of Directors of Sedline, Inc., and serves on the Board of Directors of Cercacor and the Board of Directors of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. Mr. Jensen has a JD from UCLA and B.S. from Brigham Young University, Emphasis in computer architecture, Minor in Mathematics, Phi Kappa Phi Honorary Society, magna cum laude
Travis Ault is one of the key investors of Xense. Mr. Ault served as a Platoon Leader, Executive Officer, Operations Officer and Pilot in the US. Army 1-214th Aviation Battalion in Europe. After serving in the Army, Travis joined Fieldpiece Instruments and served in multiple roles including General Manager, CEO, Corporate Director and Chairman of the Board. The company experienced exponential growth during his 13 years of leadership to become the leading supplier of Test Equipment for the HVAC industry. Mr. Ault has an MBA from USC and BS in Systems Engineering from The United States Military Academy at West Point.
With a background blended by journalism and digital marketing, Virginia is a fresh communications professional ready to show the world Xense and its cutting edge technology. She graduated from Point Park University in 2023 with a BFA in Journalism- Communications and Media Studies. Back in 2021-2022, Virginia wrote for a digital medical publication highlighting unique and innovative medical technology from around the world, inspiring her passion for the MedTech industry, which led her to Xense in October 2021.
Mr. Zschoche is a Embedded Software Engineer. Mr. Zschoche has a BS in computer science from California State University, Fullerton, where he led Systems Engineer for CSUF Titan Rover--in charge of integrating electronic and mechanical components into a cohesive system of systems.
Ming Guo, Ph.D., is a Board Member of Xense. He has many years of experience in drug research and development, regulatory, project management, corporate management, strategic planning and entrepreneurship. He is co-founder of Ascentage Pharma with various executive roles until Nov. 2021. Prior to Ascentage, Dr. Guo served in various technical and managerial roles at Pfizer. Then he worked at Ascenta Therapeutics as the founding Vice President of Pharmaceutical Sciences and Manufacturing from 2005-2010. Dr. Guo co-founded and managed Ascenta (Shanghai) R&D Center as a WOFE of Ascenta in 2005, which was one of the very first companies in China focusing on both global and local NCE drug R&D. He was an Adjunct Professor (2007-2009) followed with the role of a teaching staff as well a supervisor for master theses (2010-2017) of the IPEM program at Peking University. Dr. Guo served as the independent director at Porton Fine Chemicals Ltd. (2012-2016).
Bill Carpou is the current chief executive officer of OCTANe, Board Member of Mobix Lab, and a partner in Visionary Ventures. Prior to joining OCTANe as CEO, Mr. Carpou was the Managing Partner for TheGreyGroup which he founded and focused on revenue growth and operational improvement for early stage companies. From February 2010 through September 2014, Mr. Carpou served in an operating partner role at the Blackstone Group including leading a key portfolio company, RGIS. Mr. Carpou has a bachelor’s degree in marketing from Villanova University. He has served on the board of the Barclay Theatre, serves on the Dean’s Advisory Board at the Villanova School of Business and is a member of the Chief Executive Roundtable at the University of California, Irvine.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 4 of 4 annual reports (FY2022–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 11 filings on EDGAR- Form C-ARMay 1, 20260001923723-26-000003EDGAR
- Form C-UMay 9, 20250001665160-25-001058EDGAR
- Form C-ARMay 2, 20250001665160-25-000973EDGAR
- Form C/AFeb 21, 20250001665160-25-000290EDGAR
- Form C/AJan 16, 20250001665160-25-000074EDGAR
- Form C/ANov 19, 20240001665160-24-001649EDGAR
- Form CAug 22, 20240001665160-24-001222EDGAR
- Form C-UAug 9, 20240001665160-24-001160EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.